Results 151 to 160 of about 655,557 (182)

BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. [PDF]

Cancer Med
Luo W, Zhang Y, Li C, Xu J, Wu Z, Wang X, Kang Y, Liao D, Kou H, Xie W, Xiong W, Deng J, Mei H, Hu Y.   +13 more
europepmc   +1 more source

JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. [PDF]

J Exp Med
Saleem SK, Decker S, Kissel S, Bauer M, Chernyakov D, Bräuer-Hartmann D, Aumann K, Wickenhauser C, Herling M, Skorobohatko O, Mathew N, Schmidt C, Klein C, Follo M, Dierks C.   +14 more
europepmc   +1 more source

Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. [PDF]

Leukemia
Gambril JA, Ghazi SM, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, Kittai AS, Rogers K, Grever M, Bhat S, Wiczer T, Byrd JC, Woyach J, Addison D.   +13 more
europepmc   +1 more source

CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy. [PDF]

Eur J Haematol
Tadmor T, Melamed G, Alapi H, Rokach L.
europepmc   +1 more source

Experience of Using a Bruton Tyrosine Kinase (BTK) Inhibitor in Primary Testicular Diffuse Large B-Cell Lymphoma (DLBCL) with Isolated Central Nervous System (CNS) Metastasis. [PDF]

J Clin Pract Res
Meedimale S, Panda SS, Panda AK, Mohapatra D, Bhola RK, Moharana L, Mohanty SS, Samantaray L.   +7 more
europepmc   +1 more source

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study. [PDF]

Clin Transl Sci
Miyamoto K, Miller RM, Voors-Pette C, Oosterhaven JAF, van den Dobbelsteen M, Mihara K, Geldof M, Sato Y, Matsuda N, Kirita S, Sawa M, Arimura A.   +11 more
europepmc   +1 more source

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings. [PDF]

Front Immunol
Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B.   +34 more
europepmc   +1 more source

A fresh look at covalent BTK inhibitor resistance.

Blood
Roeker LE.
europepmc   +1 more source

BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α. [PDF]

JCI Insight
Vargas-Blanco DA, Hepworth OW, Basham KJ, Simaku P, Crossen AJ, Timmer KD, Hopke A, Brown Harding H, Vandal SR, Jensen KN, Floyd DJ, Reedy JL, Reardon C, Mansour MK, Ward RA, Irimia D, Abramson JS, Vyas JM.   +17 more
europepmc   +1 more source